Skip to main content
  • Home
  • Synopsis Article Listing
  • Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study

Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study

What was known?

All major guidelines on the primary prevention of atherosclerotic cardiovascular disease (ASCVD) with statin therapy are based on a risk calculator that estimates the 10-year risk of ASCVD. However, these risk calculators have never been evaluated in a randomised controlled trial (RCT).

Objective(s):

The aim of this study was to evaluate the extent to which statin recommendations from the American College of Cardiology/American Heart Association (ACC/AHA), Canadian Cardiovascular Society (CCS), UK National Institute for Health and Care Excellence (NICE), and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) are supported by evidence from RCTs.

What this study adds:

This analysis of a contemporary population cohort gives an insight into the evidence-base behind guideline recommended statin prescription. Among individuals eligible for statin therapy according to the ACC/AHA, CCS, NICE and ESC/EAS guidelines, the vast majority had direct RCT evidence of statin efficacy. In addition, the number needed to treat (NNT) to prevent one event is much smaller among individuals with RCT-based evidence who also fulfil guideline criteria.

Clinical implications:

These results support the use of guideline recommendations as a starting point for discussions about the initiation of primary prevention with statin therapy, as they can identify individuals who are most likely to benefit from statin therapy. However, selected individuals who do not meet guideline-based criteria for statin therapy but have RCT evidence may also benefit from statin therapy.

Study design:

This is an analysis of 79,171 individuals from the Copenhagen General Population Study (CGPS, http://www.cgps.dk), a prospective cohort study of the Danish population. The RCT evidence for statin efficacy in primary prevention of ASCVD was provided by seven high-quality RCTs. Patients underwent statin treatment according to the eligibility criteria of the different guidelines and RCTs. For each participant, the 10-year risk of ASCVD was calculated using guideline recommended prediction models. The rate of ASCVD (defined as non-fatal myocardial infarction [MI], fatal coronary heart disease [CHD], and stroke) was assessed in different groups according to whether they met guideline and/or RCT eligibility criteria. The NNT to prevent one ASCVD event in 10 years by prescribing statins was also assessed.

Study endpoint:

Clinical performance of guideline-versus RCT-based approaches

Inclusion criteria:

  • Aged 40–75
  • White and of Danish descent
  • Free of ASCVD and statin use at baseline
  • Meets statin eligibility criteria of guideline recommendations or key clinical trials

Notable exclusion criteria:

  • Pre-existing ASCVD
  • Statin use
  • Missing covariates at the baseline examination

Findings:

  • During 8.2 years of follow-up, 4031 ASCVD events occurred
  • There was a strong correlation between the 10-year risk for ASCVD/CVD and the existence of RCT data supporting statin therapy using the 4 guideline-recommended risk calculators (spearman = 0.98–1.00, p < 0.0001)
  • Among participants eligible for statin therapy with class 1A or similar recommendation according to the ACC/AHA, CCS, NICE and ESC/EAS guidelines, the majority (86%, 88%, 88% and 84%, respectively) had direct RCT evidence of statin efficacy
  • Participants eligible for statin therapy according to both guidelines and RCT evidence (guideline-positive & RCT-positive) accounted for 26–37% of the total, with guideline-positive & RCT-negative 5–7%, guideline-negative & RCT-positive 28–39%, and guideline-negative & RCT-negative 30–31%
  • The ASCVD events per 1000 person-years were 11.4–12.7 (guideline-positive & RCT-positive), 6.3–8.0 (guideline-positive &R CT-negative) , 4.2–5.2 (guideline-negative & RCT-positive), and 2.3–2.5 (guideline-negative & RCT-negative). Those in the guideline-positive & RCT-positive group had an approximately 5-fold higher risk compared with the guideline-negative & RCT-negative group (hazard ratios, 4.6 to 5.4).
  • The NNT to prevent one ASCVD event with statins in the 4 groups were 19–21, 30–32, 48–60, and 105–125, respectively

Interpretation:

These findings support the use of guideline recommendations and risk calculators for clinical decision making regarding the prescription of statin therapy, and also highlight the strong evidence base for the benefits of statin use in the primary prevention setting. The findings also raise questions that warrant further investigation, including whether individuals with RCT-based evidence of statin efficacy but without a guideline recommendation should be considered for statin therapy.

Limitations:

  • The study only included white individuals from a low risk population and may not be applicable to other ethnicities or high-risk populations
  • It was not possible to adjust for the uptake of preventive medications, including statins, during follow-up
  • Estimates of NNT to prevent one event are based on modelling and extrapolation from RCTs.
  • Only RCTs that evaluated hard ASCVD endpoints were included

Related Content

Incretin Management in Type 2 Diabetes
  • 1.00 EBAC

Learning objectives

  • Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
  • Identify underlying facets of clinical inertia in T2DM care
  • Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
  • Recall efficacy & the mode of action of various incretin-based treatments
  • Adopt an early, intensive glucose-lowering strategy in appropriate individuals 
  • Select appropriate incretin treatment & dosing regimens according to patient profiles 
  • Identify individuals likely to gain cardiovascular benefit from GLP-1RAs 
  • Select appropriate actions following adverse events from incretin-based treatments
See more
Intracoronary imaging for PCI: A practical approach to OCT
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging vs angiography-led PCI: What does success look like?
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging-based Procedure-planning with OCT: Application to Clinical Practice
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more